{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:14Z","timestamp":1790717114016,"version":"4.1.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0220681","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T17:29:55Z","timestamp":1565976595000},"page":"e0220681","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations"],"prefix":"10.1371","volume":"14","author":[{"given":"Chidimma Agatha","family":"Akpa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Kleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dido","family":"Lenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Oker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora","family":"Dimitrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"issue":"3","key":"pone.0220681.ref001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and Role of EZH2","volume":"46","author":"H Yamaguchi","year":"2014","journal-title":"Cancer. Cancer Res Treat"},{"issue":"6","key":"pone.0220681.ref002","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1389203716666150409100233","article-title":"Targeting EZH2 for Cancer Therapy","volume":"16","author":"CH Li","year":"2015","journal-title":"Progress and Perspective. Curr Protein Pept Sc"},{"issue":"4","key":"pone.0220681.ref003","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","article-title":"Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms","volume":"32","author":"R Margueron","year":"2008","journal-title":"Mol Cell"},{"issue":"3","key":"pone.0220681.ref004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00412-012-0361-1","article-title":"Inner workings and regulatory inputs that control Polycomb repressive complex 2","volume":"121","author":"MM O'Meara","year":"2012","journal-title":"Chromosoma"},{"issue":"18","key":"pone.0220681.ref005","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"C Bodor","year":"2013","journal-title":"Blood"},{"key":"pone.0220681.ref006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.humpath.2017.04.011","article-title":"EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features","volume":"64","author":"Y Liu","year":"2017","journal-title":"Hum Pathol"},{"issue":"22","key":"pone.0220681.ref007","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"JL Yan","year":"2013","journal-title":"Blood"},{"issue":"2","key":"pone.0220681.ref008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"KH Kim","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"pone.0220681.ref009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"RD Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"pone.0220681.ref010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5306\/wjco.v7.i2.135","article-title":"Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment","volume":"7","author":"I Marchesi","year":"2016","journal-title":"World J Clin Oncol"},{"issue":"5","key":"pone.0220681.ref011","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1158\/1541-7786.MCR-13-0546","article-title":"EZH2: Not EZHY (Easy) to Deal","volume":"12","author":"G Deb","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"10","key":"pone.0220681.ref012","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1541-7786.MCR-14-0034","article-title":"EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma","volume":"12","author":"SB Gao","year":"2014","journal-title":"Mol Cancer Res"},{"issue":"5","key":"pone.0220681.ref013","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation","volume":"23","author":"W Beguelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"11","key":"pone.0220681.ref014","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"SK Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"6","key":"pone.0220681.ref015","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1","volume":"8","author":"KD Konze","year":"2013","journal-title":"Acs Chem Biol"},{"issue":"9","key":"pone.0220681.ref016","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1101\/gad.1524107","article-title":"Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells","volume":"21","author":"J Tan","year":"2007","journal-title":"Gene Dev"},{"issue":"13","key":"pone.0220681.ref017","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"W Fiskus","year":"2009","journal-title":"Blood"},{"issue":"10","key":"pone.0220681.ref018","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1182\/blood-2010-07-294827","article-title":"The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML","volume":"118","author":"J Zhou","year":"2011","journal-title":"Blood"},{"issue":"22","key":"pone.0220681.ref019","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1158\/1078-0432.CCR-12-0873","article-title":"Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells","volume":"18","author":"W Fiskus","year":"2012","journal-title":"Clin Cancer Res"},{"key":"pone.0220681.ref020","first-page":"10","article-title":"Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer","author":"F Crea","year":"2011","journal-title":"Mol Cancer"},{"issue":"10","key":"pone.0220681.ref021","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1182\/blood-2010-07-294827","article-title":"The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML","volume":"118","author":"JB Zhou","year":"2011","journal-title":"Blood"},{"issue":"22","key":"pone.0220681.ref022","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1158\/1078-0432.CCR-12-0873","article-title":"Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells","volume":"18","author":"W Fiskus","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"pone.0220681.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098176","article-title":"-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells","volume":"9","author":"N Girard","year":"2014","journal-title":"Plos One"},{"issue":"6","key":"pone.0220681.ref024","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/1535-7163.MCT-09-0013","article-title":"DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation","volume":"8","author":"TB Miranda","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"pone.0220681.ref025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejps.2015.06.021","article-title":"Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus (TM)","volume":"77","author":"F Sun","year":"2015","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"pone.0220681.ref026","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and\/or BCL6 rearrangements","volume":"129","author":"P Sesques","year":"2017","journal-title":"Blood"},{"issue":"2","key":"pone.0220681.ref027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the Bcl-6 Gene as a Prognostic Marker in Diffuse Large-Cell Lymphoma","volume":"331","author":"K Offit","year":"1994","journal-title":"New Engl J Med"},{"issue":"10","key":"pone.0220681.ref028","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/modpathol.2016.92","article-title":"Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine","volume":"29","author":"RF Sun","year":"2016","journal-title":"Modern Pathol"},{"issue":"5","key":"pone.0220681.ref029","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2012.358","article-title":"U-2932: two clones in one cell line, a tool for the study of clonal evolution","volume":"27","author":"H Quentmeier","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"pone.0220681.ref030","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"H Horn","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"pone.0220681.ref031","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"H Horn","year":"2013","journal-title":"Blood"},{"issue":"5","key":"pone.0220681.ref032","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10428194.2015.1108414","article-title":"Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas","volume":"57","author":"HG Drexler","year":"2016","journal-title":"Leukemia Lymphoma"},{"issue":"8","key":"pone.0220681.ref033","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","article-title":"A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma","volume":"123","author":"I Salaverria","year":"2014","journal-title":"Blood"},{"issue":"9","key":"pone.0220681.ref034","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-10-2156","article-title":"Aberrations of EZH2 in Cancer","volume":"17","author":"A Chase","year":"2011","journal-title":"Clinical Cancer Research"},{"issue":"1\u20132","key":"pone.0220681.ref035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"JA Simon","year":"2008","journal-title":"Mutat Res"},{"issue":"2","key":"pone.0220681.ref036","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/bjc.2011.551","article-title":"The role of EZH2 in tumour progression","volume":"106","author":"CJ Chang","year":"2012","journal-title":"Brit J Cancer"},{"issue":"8","key":"pone.0220681.ref037","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2014-10-606822","article-title":"Polycomb genes, miRNA, and their deregulation in B-cell malignancies","volume":"125","author":"GG Wang","year":"2015","journal-title":"Blood"},{"issue":"3","key":"pone.0220681.ref038","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.18632\/oncotarget.6198","article-title":"EZH2 in normal hematopoiesis and hematological malignancies","volume":"7","author":"L Herviou","year":"2016","journal-title":"Oncotarget"},{"issue":"6907","key":"pone.0220681.ref039","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"S Varambally","year":"2002","journal-title":"Nature"},{"issue":"2","key":"pone.0220681.ref040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"IM Bachmann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"pone.0220681.ref041","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"AP Bracken","year":"2003","journal-title":"Embo J"},{"issue":"19","key":"pone.0220681.ref042","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","article-title":"A687V EZH2 is a gain-of-function mutation found in lymphoma patients","volume":"586","author":"CR Majer","year":"2012","journal-title":"Febs Lett"},{"issue":"7360","key":"pone.0220681.ref043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"RD Morin","year":"2011","journal-title":"Nature"},{"issue":"10","key":"pone.0220681.ref044","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"JG Lohr","year":"2012","journal-title":"P Natl Acad Sci USA"},{"issue":"8","key":"pone.0220681.ref045","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"MT McCabe","year":"2012","journal-title":"P Natl Acad Sci USA"},{"issue":"12","key":"pone.0220681.ref046","article-title":"EZH2 Codon 641 Mutations are Common in BCL2-","volume":"6","author":"RJH Ryan","year":"2011","journal-title":"Rearranged Germinal Center B Cell Lymphomas. Plos One"},{"issue":"8","key":"pone.0220681.ref047","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"DB Yap","year":"2011","journal-title":"Blood"},{"issue":"49","key":"pone.0220681.ref048","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"CJ Sneeringer","year":"2010","journal-title":"P Natl Acad Sci USA"},{"issue":"1","key":"pone.0220681.ref049","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CCO.0000000000000151","article-title":"Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention","volume":"27","author":"C Shen","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"pone.0220681.ref050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.apsb.2015.01.011","article-title":"DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis","volume":"5","author":"M Sha","year":"2015","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"pone.0220681.ref051","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.lungcan.2012.08.003","article-title":"Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells","volume":"78","author":"J Kikuchi","year":"2012","journal-title":"Lung Cancer"},{"issue":"2","key":"pone.0220681.ref052","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/or.2013.2922","article-title":"Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells","volume":"31","author":"S Nakagawa","year":"2014","journal-title":"Oncol Rep"},{"issue":"3","key":"pone.0220681.ref053","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1158\/2159-8290.CD-12-0012","article-title":"Circumventing Cancer Drug Resistance in the Era of Personalized Medicine","volume":"2","author":"LA Garraway","year":"2012","journal-title":"Cancer Discov"},{"issue":"3","key":"pone.0220681.ref054","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"G Housman","year":"2014","journal-title":"Cancers (Basel)"},{"issue":"11","key":"pone.0220681.ref055","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.chembiol.2014.09.017","article-title":"EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation","volume":"21","author":"WD Bradley","year":"2014","journal-title":"Chem Biol"},{"issue":"4","key":"pone.0220681.ref056","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma","volume":"13","author":"SK Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"7427","key":"pone.0220681.ref057","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"MT McCabe","year":"2012","journal-title":"Nature"},{"issue":"11","key":"pone.0220681.ref058","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0840","article-title":"EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL","volume":"16","author":"D Brach","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"pone.0220681.ref059","doi-asserted-by":"crossref","first-page":"S278","DOI":"10.1016\/j.clml.2018.07.208","article-title":"Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R\/R) Follicular Lymphoma (FL)","volume":"18","author":"J Pagel","year":"2018","journal-title":"Cl Lymph Myelom Leuk"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0220681","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:29:27Z","timestamp":1588998567000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0220681"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0220681","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]}}}